Skip to main content

Dealing with Unmanageable Seizures?

Explore Generalized Epilepsy Clinical Trials In Illinois & Michigan Investigating Novel Treatment Options

Epilepsy is a neurological condition characterized by recurrent myoclonic seizures due to abnormal brain activity. Management typically involves medications, lifestyle adjustments, and sometimes surgical intervention. Treatment aims to reduce seizure frequency and improve quality of life.

Revive Research Institute is conducting Generalized Epilepsy Clinical Trials in Illinois & Michigan investigating novel treatments that may be able to help you and countless others manage symptoms of Epilepsy.

You may qualify for the paid Epilepsy Clinical Trial near you if you are:

  • Male or female, aged 18 to 75 years
  • Diagnosis of Idiopathic Generalized Epilepsy (IGE) at least 6 months prior
    *Additional criteria may apply

*Take part in paid Generalized Epilepsy Clinical Trials in Illinois or Michigan at no cost to you or your medical insurance. You will be reimbursed financially for your time and travel. In addition, all participants receive study-related care from an experienced research team.

*If you are interested in participating in the Epilepsy Clinical Trials or would like more information, please fill out the form so we can determine if you qualify for the study and contact you. Note that this is an entirely voluntary decision.

Please provide YOUR contact information only.
For more info, please visit Privacy Policy.
Multiple Sclerosis Clinical Trials Flyer

About Generalized Epilepsy Clinical Trials

Epilepsy, a neurological disorder affecting millions worldwide, requires ongoing research to develop effective treatments. Revive is currently conducting Generalized Epilepsy Clinical Trials in Illinois & Michigan, aiming to evaluate the safety and efficacy of an investigational medication in adult males and females (age 18 to 75) with a diagnosis of Idiopathic Generalized Epilepsy (IGE) at least 6 months before the screening visit. Your involvement can contribute to advancements in epilepsy care.

The potential treatment for generalized epilepsy under investigation in this clinical trial will last for 78 weeks. To ensure study eligibility, all participants must comply with all study procedures. We are looking into the safety and efficacy of an oral investigational drug used to treat uncontrollable myoclonic seizures in epilepsy.

*There is no cost to you, your private medical insurance, or the public health insurance plan for study procedures. The study drug, related procedures, and visits will be provided at no charge for the duration of the Generalized Epilepsy Clinical Study in Illinois & Michigan.

Get Started: What to Expect?

If you are struggling in finding treatment for Generalized Epilepsy Seizures, this study may be for you. This study evaluates the safety and efficacy of an investigational medication in adults who are no longer responding to traditional treatment.

After completing the online form above, someone from the research team will contact you to determine whether you are a good fit for the Generalized Epilepsy Clinical Trial currently underway. After your eligibility is confirmed, you will be asked to sign an Informed Consent Form (ICF). This will take place during a screening/introductory visit, when interested participants may be requested to visit the clinical site. Following your signature, you will be asked a series of questions about your health and medical history, as well as subjected to a few tests to make sure that you fulfill the eligibility criteria of the study.

If you fulfill the criteria and decide to participate in the Generalized Epilepsy Clinical Trial, the study may last for approximately 78 weeks. You will be given a placebo or the study drug, which is potential therapy, during this time. The placebo is a drug without active ingredients. Neither you nor your study doctor will know which drug you receive.

*All study-related care is provided free of cost. Complete physical examination and other study-related assessments will be done by expert physicians and health care experts.

Length of study

78 weeks

No. of Study Visits

7-8 visits

Location

Illinois & Michigan

About Generalized Epilepsy

Epilepsy is a neurological disease associated with myoclonic seizures along with abnormal activity in the brain. Epilepsy with Generalized Tonic-clonic Seizures is a syndrome of unprovoked seizures impacting about 1.2% of the adult population, making it the most common neurological condition.

Symptoms

  • Loss of consciousness
  • Sudden stiffening of the body (tonic phase)
  • Rhythmic jerking movements (clonic phase)
  • Tonic-clonic myoclonic seizures often last 1 to 3 minutes
  • Incontinence (loss of bladder or bowel control)
  • Tongue biting or cheek biting
  • Post-seizure confusion or disorientation
  • Fatigue or sleepiness after the seizure
  • Headache or muscle soreness post-seizure

Frequently Asked Questions (FAQs)

1. What is Epilepsy?

Epilepsy is a neurological disorder characterized by recurrent seizures. These seizures are caused by abnormal electrical activity in the brain.

2. What are generalized tonic-clonic seizures?

Generalized tonic-clonic seizures, formerly known as grand mal seizures, are a type of seizure that affects both hemispheres of the brain. They typically involve loss of consciousness, stiffening of the body (tonic phase), followed by rhythmic jerking movements (clonic phase).

3. What causes generalized tonic-clonic seizures?

Generalized tonic-clonic seizures can have various causes, including genetic factors, brain injury, infection, stroke, brain tumor, or developmental disorders.

4. Will my medical information be kept private if I decide to participate in the clinical trial?

Your personal health information will be handled privately by the research doctor and study staff. All your personal and health-related information will be kept private under the privacy rule of HIPAA.

5. How do I know if I am eligible to be a part of the Generalized Epilepsy Clinical Trials?

Every clinical trial has a strict criterion of who should be included or excluded from the study. Your age, gender, the type and stage of your disease, previous treatment history, and other medical conditions are some of the points of eligibility criteria. If you would like to participate in finding treatment of Generalized Epilepsy Clinical Trials in Illinois or Michigan, please have a look at the eligibility criteria above and fill out the form.

Close Menu

Revive Research Institute, Inc.

28270 Franklin Road
Southfield, MI
48034

T: 248-564-1485
E: info@rev-research.com